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Abstract
Background: Quantitative real-time RT-PCR (RT-qPCR) has become a valuable molecular
technique in basic and translational biomedical research, and is emerging as an equally valuable
clinical tool. Correlation of inter-sample values requires data normalization, which can be
accomplished by various means, the most common of which is normalization to internal, stably
expressed, reference genes. Recently, such traditionally utilized reference genes as GAPDH and
B2M have been found to be regulated in various circumstances in different tissues, emphasizing the
need to identify genes independent of factors influencing the tissue, and that are stably expressed
within the experimental milieu. In this study, we identified genes for normalization of RT-qPCR data
for invasive breast cancer (IBC), with special emphasis on estrogen receptor positive (ER+) IBC,
but also examined their applicability to ER- IBC, normal breast tissue and breast cancer cell lines.
Methods: The reference genes investigated by qRT-PCR were RPLP0, TBP, PUM1, ACTB, GUS-
B, ABL1, GAPDH and B2M. Biopsies of 18 surgically-excised tissue specimens (11 ER+ IBCs, 4 ER-
IBCs, 3 normal breast tissues) and 3 ER+ cell lines were examined and the data analyzed by
descriptive statistics, geNorm and NormFinder. In addition, the expression of selected reference
genes in laser capture microdissected ER+ IBC cells were compared with that of whole-tissue.
Results: A group of 3 genes, TBP, RPLP0 and PUM1, were identified for both the combined group
of human tissue samples (ER+ and ER- IBC and normal breast tissue) and for the invasive cancer
samples (ER+ and ER- IBC) by GeNorm, where NormFinder consistently identified PUM1 at the
single best gene for all sample combinations.
Conclusion: The reference genes of choice when performing RT-qPCR on normal and malignant
breast specimens should be either the collected group of 3 genes (TBP, RPLP0 and PUM1)
employed as an average, or PUM1 as a single gene.
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Prognostic and predictive molecular markers associated
with breast cancer are allowing individualization of treat-
ment, and quantitative real-time RT-PCR is frequently
used to measure the expression of these markers. The
advantages of this technique are numerous, including its
ability to sensitively quantify specific mRNA despite small
samples sizes or low numbers of mRNA [1-4]. Working
with absolute quantities based on standard curves is time-
consuming and laborious. A target gene can be analyzed
much more easily and precisely by correlation to a stable
independent parameter, i.e. directly proportional to the
amount of mRNA and not influenced by factors such as
hormones, cell cycle status, etc. This technique is termed
'normalization', and the prevailing method is the use of
reference genes [5].
The primary advantage of using genes expressed within
the cells investigated as reference genes is that they also
function as endogenous controls, since they are exposed
to the same conditions in vivo and in vitro, thereby provid-
ing a direct indication of the quantity and quality of the
samples. Widely-used genes include β-actin (ACTB),
glydecaldehyde-3-phosphate-dehydrogenase (GAPDH)
and β-2-microglobulin (B2M). However, it has recently
become clear that the expression of some of these genes
may be modulated during cellular processes such as differ-
entiation and cancer progression, and are also susceptible
to hormonal influences [1,5] as exemplified by β2-
microglobulin and GAPDH. B2M have been found to be
influenced by factors present in brain cortices of human
chronic alcoholics [6]. GAPDH have been reported to be
regulated by oestradiol, showing a dose-dependent, statis-
tically-significant, increase in expression in MCF-7 cells
[7]. Despite this shortcoming, however, GAPDH contin-
ues to be utilized as a normalizer in investigations of
breast cancer and cell lines by RT-qPCR.
It is therefore necessary to identify appropriate reference
genes for each experimental set-up. This is especially
important for studies investigating subtle differences in
the analyzed sub-groups, since such studies are more sen-
sitive to minor fluctuations of the reference gene(s) that
could lead to an incorrect rating of the target gene expres-
sion levels. It is also now widely accepted that more than
one reference gene is needed to reduce the sensitivity to
degraded material and to varying amounts of input RNA
[8,9].
Approximately 80% of all invasive breast cancers (IBCs)
are estrogen receptor positive (ER+), meaning they express
the ER above a cut-off value, usually 5–10%, as deter-
mined by immunohistochemistry (IHC). These patients
are eligible for endocrine treatment such as Tamoxifen
that specifically target the ER, or the newer aromatase
inhibitors (AI) that target the aromatase enzyme,, prevent-
ing estrogen synthesis. Unfortunately, about 30% of these
patients do not benefit from Tamoxifen treatment and
reports of relapse after AI are emerging [10,11]. These
results have prompted many studies to elucidate this
"anti-estrogen resistance", and RT-qPCR is a widely used
technique in such studies. Although the cancers in these
patients express the ER at the protein level, which is one
of the routinely applied predictive markers to date for this
breast cancer sub-type, it is likely that there are underlying
molecular defects that render them unresponsive either
through de novo or acquired resistance. The desire to fur-
ther sub-group these patients has led to investigation of
gene expression, which has highlighted the need for sta-
ble, hormone-independent, normalizers.
Two computer programs that allow relative identification
of reference genes have been developed for Microsoft
Excel® either as a Visual Basic Application tool (geNorm
[12]) or as an Add-in (NormFinder [13]), which can be
used to objectively pinpoint the appropriate genes.
Briefly, geNorm ranks the genes according to the average
pair-wise variation of a particular gene with all other
genes, and also provides a measure of the minimum opti-
mal number of reference genes to avoid the expense and
'noise' in the assay from using too many reference genes.
NormFinder calculates the stability value for all candidate
normalization genes, providing a rank order and direct
estimation of expression variation. Moreover, it provides
the option of defining sub-groups among the samples the
reference genes are tested on, such as tumor grade, size,
etc.
In this study, we systematically evaluated a panel of
endogenously expressed genes to identify those that
would be most useful in normalization of RT-qPCR data
from ER+ IBCs. In addition, we investigated whether these
genes might also be useful in ER- IBCs, normal tissue and
breast cancer cell lines.
We identified a 3-gene group (TATA-box binding protein
(TBP), Ribosomal protein, large, P0 (RPLP0) and
homolog of Pumilio, Drosophila, 1 (PUM1)) to be the
most suited for normalization of RT-qPCR data in both
the collected group of human breast tissue samples (ER+
and ER- IBC and normal breast tissue) and the IBCs (ER+/
ER-). These genes should be used if employing an aver-
aged normalization strategy. Should finances or limited
amount of material only allow a single gene be used for
normalization, PUM1 was identified for all of the above
mentioned samples as the single best gene.Page 2 of 11
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▪ Cells
Three ER+ cell lines, T47D (HTB-133, American Type Tis-
sue Culture (ATCC), Manassas, VA), MCF-7 (HTB-22,
ATCC) and BrCa-MZ-01 [14] were used. T47D was grown
in RPMI1640 with 2 mM L-glutamine, containing 1.5 g/L
sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0
mM sodium pyruvate, supplemented with 0.2 U/mL
bovine insulin (90%) and 10% fetal bovine serum. MCF-
7 were grown in minimum essential medium (Eagle) with
2 mM L-glutamine, containing 1.5 g/L sodium bicarbo-
nate, 0.1 mM non-essential amino acids, 1.0 mM sodium
pyruvate, supplemented with 0.01 mg/mL bovine insulin
(90%) and 10% fetal bovine serum. BrCa-Mz-01 was
grown in DMEM with high glucose, 1% non-essential
amino acids, 1% L-glutamine, 1% sodium pyruvate, 1%
fetal calf serum and 1% Penicillin/Streptomycin. All were
incubated at 37°C, with 95% air and 5% CO2. The cells
were counted, pelleted by centrifugation at 2.3 × g for 3
min and stored at a concentration of 5 × 106 cells/mL in
MagNa Pure LC mRNA isolation kit I lysisbuffer (Roche,
Mannheim, Germany) at -80°C for a maximum of 2
months. The cells were verified as ER+ by immunohisto-
chemistry.
▪ Tissue sampling
Eleven ER+ and 4 ER- breast carcinomas from patients
undergoing primary surgery at Odense University Hospi-
tal were included in the study. Mean age 62 years (range
44–90 years), mean tumor size 26 mm (range 8–45 mm),
malignancy grade 1–3. All ER+ tumors were 100% posi-
tive for ER as determined by IHC. Three normal breast tis-
sue samples were obtained from breast reductive surgery.
A 0.5 × 0.5 cm piece of each sample was snap frozen
within 30 minutes of excision in isopentane after covering
with TissueTek (Sakura Finetek, Zoeterwoude, The Neth-
erlands) and stored at -80°C until use. Sections of each
carcinoma were stained with haematoxylin/eosin to deter-
mine the percentage of tumor cells, which was confirmed
to be >50% in all instances. Tumor tissue (30 mg) was
homogenized in 800 μL lysisbuffer (Roche) using MagNa
Lyser Green beads/MagNa Lyser instrument (Roche) for
two 10 sec pulses at 6.500 rpm, and stored at -80°C for a
maximum of 2 months. The study was approved by the
ethical committee of Funen and Vejle County, Denmark.
▪ Laser Capture Microdissection (LCM)
To specifically evaluate gene expression in isolated breast
cancer cells, one ER+ breast cancer sample underwent
LCM to isolate the tumor cells. To avoid amplification of
RNA, LCM of 16 tissue slides were pooled, yielding a con-
centration of 10.72 ng/μL (NanoDrop ND-1000 Spectro-
photometer, V3.1 (NanoDrop Technologies, Wilmington,
DE)). In brief, cryosections (7 μm) were cut and applied
to slides. Pretreatment of the slides was as follows: Sec-
tions were thawed for 15–30 sec (without hydration),
70% EtOH was applied for 30 sec, 15–30 sec hydration in
DEPC-treated water, haematoxylin-stained by dipping ×3
in solution. Samples were then washed with DEPC-
treated water and dipped in autoclaved tap-water to inten-
sify nuclear staining, placed in 70% EtOH for 30 sec, 96%
EtOH for 30 sec, 1–2 dip in eosin solution, 96% EtOH for
30 sec, two times 100% EtOH for 30 sec (separate vials)
and xylene for 4 min. The slide was then placed in a fume
hood for 5 min to air-dry the xylene. LCM was conducted
for a maximum of 1 hr to ensure reliability of RNA integ-
rity. LCM was carried out on the PixCell® IIe (Arcturus Bio-
science Inc., CA) isolating total RNA using the RiboPure
RNA isolation kit (Arcturus) with 50 μL extraction buffer,
according to manufacturer's protocol.
▪ RNA purification
RNA was purified from 350 μL of lysis buffer containing
the cell lines or the homogenized tissue samples by Roche
RNA isolation kits for cells or tissue, respectively (MagNa
Pure LC RNA isolation kit III tissue and MagNa Pure LC
RNA isolation kit – high performance) using the MagNa
Pure Robot (Roche). This system uses magnetic beads to
isolate total RNA. Concentration and purity (260/280
ratio) were measured in duplicate by the NanoDrop
(NanoDrop Technologies), achieving a mean concentra-
tion of 16.9 ng/μL (3.22 – 60.45 ng/μL) and a 260/280-
ratio of 1.99 ± 0.2 (SD). RNA obtained from cell cultures
and frozen tissue was not significantly degraded, as deter-
mined by gel electrophoresis (data not shown).
▪ cDNA synthesis
Total RNA (10 μL) was reverse-transcribed to cDNA using
random 9 oligonucleotide primers at 25 μM per reaction.
RNA and primers were incubated for 5 min at 70°C and
subsequently placed on ice. A reaction mix consisting of 1
mM dNTPs, 1 Unit/μL RNase Inhibitor (Roche), 10 Unit/
μL Reverse Transcriptase (Invitrogen Life Technologies,
Paisley, UK) and First Strand Buffer ×5 (Invitrogen) was
added and incubated for 10 min at 25°C, followed by 45
min at 37°C, and 5 min at 95°C.
▪ Quantitative real-time RT-PCR (RT-qPCR)
The TaqMan® Gene Expression Assays (Applied Biosys-
tems, Foster City, CA, USA) were used for all reactions for
the genes shown in table 1. The existence of pseudogenes
was investigated by BLAT search [15], analyzing the
sequence of the entire potential amplicon, as the precise
cDNA sequence was unavailable. This BLAT search was
devised as the assay location ± amplicon size provided +
around 10 bp at each end. The presence of pseudogenes,
and thereby possible cross-reactivity with gDNA, was
defined as regions of >95% identity for an approximately
equal length to the potential amplicon. The 25 μL RT-
qPCR reaction mix contained 1× TaqMan universal mas-Page 3 of 11
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cDNA, gDNA or dilution series, and RNase/DNase-free
water. The reactions were run for 2 min at 50°C, 10 min
at 95°C, followed by 50 cycles of 15 seconds at 95°C and
1 min at 60°C. All RT-qPCR reactions were performed on
the ABI 7900 HT system (Applied Biosystems) and were
measured in replicate (triplicate or duplicate) to ensure
methodological reproducibility, which was within a max-
imum of 0.24 Ct's. The detection limit was set at Ct 41.
Since we used assays-on-demand, we wanted to verify per-
formance of the primer and probe sets. The reference
genes were methodologically analyzed by a 10-fold dilu-
tion series of cDNA from MCF-7 in water (1-1:100.000) to
ensure optimal amplification efficiency. In addition, the
4-group reference genes for ER+ IBC were analyzed by a
dilution series in MCF-7 derived gDNA (1-1:10.000) to
test for competitive binding. TissueTek and the tissue itself
were also tested for inhibitory components. To examine
the effect of TissueTek on the PCR, a 2-fold dilution series
was conducted with cDNA from MCF-7 and TissueTek
(1:2 – 1:16) treated identically to patient tissue from freez-
ing in isopentane to cDNA synthesis (included), using the
expression assay for β2M. Only a minimal increase, i.e.
inhibition of the PCR reaction, was observed for the 1:2
dilution, raising the Ct by 0.7. It was therefore concluded
that TissueTek does not need to be macro-dissected from
tissue sections since it is never found in such excess in
patient tissues. A 10-fold dilution series was conducted on
one patient's cDNA using the reference gene TBP to test for
inhibitory components in the tissue. No inhibition was
observed (amplification efficiency 2.0). Calculations for
the amplification efficiency were = , where α is the
slope of the standard curve obtained by a dilution series,
plotted as Ct-value (y-axis, linear values) versus the dilu-
tion (x-axis, logarithmic values).
▪ PCR
A PCR was performed with the same program as RT-qPCR
for the 4-group reference genes for ER+ IBC with cDNA
from one patient (no. 9) and the MCF-7 cell line. The
products were run on a 3% NuSieve GTG agarose gel
(Cambrex Bioscience Rockland Inc., Rockland, ME) with
20 μg EtBr (Sigma, St. Louis, MO) in 1× TBE buffer
(Sigma) at 5 V/5 min followed by 100 V/45 min (BioRad,
Hercules, CA) along with a PCR marker (New England
BioLabs Inc., Ipswich, MA).
▪ Immunohistochemistry (IHC)
The NCL-ER-6F11 antibody (Novocastra Ltd., Newcastle,
UK) was used for ER detection. Antigen retrieval was per-
formed using Tris-EGTA, pH 9, incubated overnight at
10a
Table 1: Summary of candidate reference genes. 
Symbol Gene name (Assay ID) Function Location Assay location 
(amplicon size)
PG¥ A/CB #
RPLP0 
NM_053275.3
Ribosomal protein, large, P0 
(Hs99999902_m1)
Structural protein of ribosomes 12q24.2 325* • (105) + (-/+)
TBP 
NM_003194.3
TATA box binding protein 
(Hs00427620_m1)
Transcription factor; DNA-
dependent transcription initiation 
from Pol II promoter
6q27 730 (91) - (-/-)
PUM1 
NM_001020658.1
Pumilio homolog (Drosophila) 
(Hs00982765_m1)
RNA binding; translation factor. 1p35.2 1757 (68) - (-/-)
ACTB 
NM_001101.2
β-actin (Hs99999903_m1) Cytoskeletal structural protein 
involved in various types of cell 
motility
7p22-p12 36* × • (171) + (-/+)
GUS-B 
NM_000181.1
Glucoronidase, beta 
(Hs99999908_m1)
Hydrolase; carbohydrate 
metabolism.
7q21.11 1816 (81) - (-/NI)
ABL1 
NM_005157.3
v-abl Abelson murine leukemia 
viral oncogene homolog 1 
(Hs00245443_m1)
Protein kinase; regulation of cell 
cycle, mismatch repair, DNA 
damage response
9q34.1 85 (54) - (-/NI)
GAPDH 
NM_002046.3
Glyceraldehyde-3-phosphate 
dehydrogenase 
(Hs99999905_m1)
Oxidoreduct-ase; glucose 
metabolism
12p13.31-p13.1 158* × • (122) - (+/NI)
B2M 
NM_004048.2
β-2-microglobulin 
(Hs00187842_m1)
Major histocompati-bility complex 
antigen class 1 receptor activity
15q21-q22 128 • (64) - (-/NI)
NI: not investigated. 
¥: PG = pseudogenes. BLAT search to identify pseudogenes of potential amplicons. See materials and methods for criteria. 
#: Experimentally observed to A = amplify gDNA or CB = competitive binding of primers or probe with gDNA. 
*: amplicon does not cross exon-exon boundaries. 
×: known pseudogenes exist. These genes have been designed to amplify a region of the 5'UTR.
•: SNP(s) are located under a primer or probe sequencePage 4 of 11
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H2O2 for 10 min. The primary antibody (1:100) was incu-
bated for 60 min and detected by PowerVision (Immuno-
vision Technologies, Fullerton, CA, USA), followed by
nuclear counter-staining with Mayers Haematoxylin for 2
min. All immunostainings were performed using the
Autostainer (Dako) and known positive and negative con-
trols were included. The steroid receptors were scored pos-
itive if > or = 10% of the tumor cells had nuclear staining.
▪ Data analysis and statistics
The RT-qPCR raw data was analyzed using the SDS soft-
ware, vers. 2.1 (Applied Biosystems). Descriptive statistics
were conducted using box-plots (STATA, vers. 9, TX). The
RT-qPCR raw data was converted to linear values compat-
ible with the geNorm and NormFinder programs by
qBase, v.1.3.4. (Visual Basic application tool for Microsoft
Excel available on the Internet) [16]. For stability compar-
isons of candidate reference genes, the software geNorm,
vers. 3.4 [12] (Visual Basic application tool for Microsoft
Excel, available on the Internet) and NormFinder [13] (a
Microsoft Excel Add-in available on the Internet) were
used according to author's recommendations. In addi-
tion, the option in NormFinder to define sub-groups was
applied for ER+ IBC patients for important prognostic fac-
tors such as number of positive lymph nodes, tumor size
and malignancy grade. The sub-groups were defined as
follows: Lymph nodes – 3 groups; 0 (n = 3), 1–3 (n = 5)
and >4 (n = 3) lymph nodes with metastasis. Tumor size
– 2 groups; ≤ 20 mm (n = 5) and > 20 mm (n = 6). Malig-
nancy grade – 3 groups; grade 1 (n = 3), grade 2 (n = 4)
and grade 3 (n = 4).
Results
Selection of candidate genes
Eight genes were selected for investigation to identify the
most stably-expressed reference gene to be used in RT-
qPCR studies of breast cancer, with specific emphasis on
ER+ IBC. The 8 candidates were selected based on previ-
ous reports on RT-qPCR studies examining IBCs (RPLP0,
TBP and PUM1) [17-19] or were commonly used refer-
ence genes (ACTB, GUS-B, ABL1, GAPDH and B2M)
(Table 1).
Performance of the RT-qPCR assays
The 8 reference genes were tested for possible amplifica-
tion of genomic DNA to ensure that the observed amplifi-
cation was not the result of genomic DNA in the RNA-
purified sample. No amplification was observed for the
genes, with the exception of GAPDH, which weakly
amplified genomic DNA from MCF-7 cells at an absolute
Ct' of 37.0. The PCR assays were assessed since they con-
tained pre-designed primer-probe sets (Table 2) and the
primer and probe sets were confirmed to have performed
perfectly, with an amplification efficiency of 1.9–2.0. In
addition, the specificity was investigated by PCR and gel
separation, confirming an expected single band at the
reported amplicon size, as shown in Table 1.
Descriptive statistics
The absolute expression levels of the 8 reference genes in
the 11 ER+ IBCs (Fig. 1) were observed spanning on aver-
age a Ct value of 7.2 between the most abundant (β2M)
and least abundant genes (TBP). Interestingly, TBP was
consistently the least abundant gene in all sample types
investigated, whereas the most abundant gene varied
between sample groups. For ER+ tumors and normal
breast tissue, β2M was the most abundant, for ER- tumors
and cell lines it was ACTB and GAPDH, (Fig. 2).
Identification of optimal reference genes
Initially, the absolute Ct values for the samples were
graphed to visualize the stability of the genes (Fig. 1).
However, this graphic representation clearly illustrated
Table 2: Performance of the qPCR. Standard curve results are summarized and the amplification efficiency calculated. 
Dilutant
Water gDNA
Genes Slope R2 Amplification efficiency Slope R2 Amplification efficiency
PUM1 -3.49 0.998 1.9 -3.47 0.998 1.9
TBP -3.36 0.988 2.0 -3.27 0.998 2.0
RPLP0 -3.56 0.999 1.9 -5.70 0.924 1.5*
ACTB -3.52 0.999 1.9 -4.91 0.940 1.6*
GAPDH -3.27 0.999 2.0
B2M -3.45 0.998 2.0
ABL -3.41 0.999 2.0
GUS-B -3.33 0.998 2.0
Dilution in gDNA was conducted to investigate competitive binding for the 4-group reference genes for ER+ IBC. 
*: theoretical amplification efficiencies. The actual efficiency cannot be determined since the standard curves were flawed, as observed by the low 
coefficient of correlation (R2)Page 5 of 11
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of statistical analysis was not possible. The two most com-
monly utilized computer programs developed to identify
the most suitable reference genes in various applications
are geNorm [12] and NormFinder [13]. These programs
were used in our study to analyze expression of the candi-
date reference genes in different sample types. GeNorm
identifies the optimal genes and how many are required
for optimal stability by pair-wise comparisons, whereas
NormFinder enables identification of the single best genes
as a ranking order. Table 3 summarizes the results of this
analysis and shows the optimal reference gene(s) of the
individual sample groups and combinations thereof.
When examining the 18 patient tissue specimens (ER+/
ER- IBC/normal) or the breast cancer tissue specimens
alone (ER+/ER- IBC), the 3-gene combination of RPLP0,
TBP and PUM1 were consistently identified by geNorm to
exhibit the highest degree of stability. For ER+ IBC sam-
ples alone, geNorm identified the same set of 3 genes
mentioned above, but a fourth gene (β-actin) was recom-
mended for increased stability. When the cell lines were
also included, a fifth gene (GUS-B) was additionally rec-
ommended to obtain the highest degree of stability.
NormFinder uniformly identified the PUM1 gene as the
single most stable gene for all sample combinations, as
well as the ER+ IBC group alone (Table 3).
The 4-group reference genes identified for ER+ IBC,
RPLP0, PUM1, TBP and β-actin (geNorm), were addition-
ally tested for competitive binding to genomic DNA by a
dilution series in genomic DNA to examine the necessity
of DNase treatment of purified RNA. Reduced amplifica-
tion efficiencies for RPLP0 and ACTB were observed
(Table 2), underscoring the importance of DNase treat-
ment in these two assays.
Evaluation of possible influence of prognostic factors on 
reference gene expression in ER+ IBCs
NormFinder has the option of defining groups within the
samples, and was utilized to confirm that important prog-
nostic parameters such as the number of positive lymph
nodes, tumor size and malignancy grade did not influence
selection of the identified optimal reference genes for the
ER+ IBC group (Fig. 3). As relatively few samples were
Absolute Ct values of 11 ER+ (1–11) and 4 ER- (A-E) IBCs, 3 normal breast tissue samples (N-1 – N-3) and 3 ER+ cell lines (T47D, M F-7 and BrCa)Figure 1
Absolute Ct values of 11 ER+ (1–11) and 4 ER- (A-E) IBCs, 3 normal breast tissue samples (N-1 – N-3) and 3 
ER+ cell lines (T47D, MCF-7 and BrCa). All genes were investigated using the same RNA/cDNA batch per sample. A) all 
investigated reference genes. B) the 4-group reference genes for ER+ IBC.Page 6 of 11
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should be viewed as representing an interesting tendency
needing further investigation.
Laser capture microdissection of ER+ tumor cells
To specifically examine the reference gene expression of
ER+ IBC cells from patient tissue, tumor cells from one
ER+ IBC patient were laser capture microdissected. The
analysis showed nearly parallel expression to whole-tissue
from the same tumor using the 4-group reference genes
for ER+ IBC of TBP, RPLP0, PUM1 and ACTB (Fig. 4), as
observed by a Pearson correlation of 0.992. β-actin and
TBP had an absolute Ct difference of 3.2, whereas PUM1
and RPLP0 had an absolute difference of 2.5, giving an
absolute variation of only 0.7 Ct's.
Discussion
The importance of reference genes specific to a particular
experimental set-up for normalization of RT-qPCR data is
well-recognized. However, the use of multiple reference
genes rather than a single gene remains a matter of debate,
although it is widely accepted that multiple genes mini-
mize the influence of minor fluctuations [12].
Table 3: Summary of top candidate reference genes identified by geNorm and NormFinder. For the geNorm data, the optimal 
number and identity of reference genes proven necessary by a Pairwise variation below 0.15, as recommended by Vandesompele et al. 
[12], is provided in the order given by the program. The stated genes should be viewed per program, and the combination of genes 
provided by geNorm cannot be used as single entities as optimal reference genes. The number of patients included was: ER+ (n = 11), 
ER- (n = 4), normal (n = 3) and ER+ cell lines (n = 3)
geNorm NormFinder
ER+, ER-, normal and cell lines RPLP0/TBP, PUM1, GUS-B and β-actin PUM1 PUM1/RPLP0
ER+, ER- and normal tissue TBP/PUM1 and RPLP0 PUM1 PUM1/RPLP0
ER+ and ER- TBP/PUM1 and RPLP0 PUM1 PUM1/RPLP0
ER+ RPLP0/TBP, PUM1 and β-actin PUM1
ER- PUM1/GUS-B and RPLP0 β-actin
Normal* PUM1/GUS-B and TBP TBP
ER+ cell lines TBP/PUM1 ABL
* initially geNorm identified GAPDH/RPLP0 and TBP as the best candidates. GAPDH was found earlier to cross-react to pure genomic DNA and 
was therefore removed from the panel.
Box plot of the absolute Ct values of the 8 reference genes investigated on the 4 sub-groupsFigure 2
Box plot of the absolute Ct values of the 8 reference genes investigated on the 4 sub-groups. The same batch of 
RNA/cDNA was used for each patient across the genes.Page 7 of 11
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conventional and novel potential reference genes for accu-
rate normalization of real-time RT-qPCR data in breast
cancer. The use of a liquid handling robot, high quality
real-time PCR reagents and commercially available
expression assays designed to maximize PCR efficiency
and specificity allows trustworthy comparison of genes.
The reference genes were evaluated using ER+ and ER-
IBC, normal breast tissue and ER+ cell lines, and the data
were analyzed using 1) descriptive statistics (i.e. boxplot
and absolute value comparisons), 2) geNorm and 3)
NormFinder programs that identified the most stably
expressed genes. The top 4 genes were also evaluated using
laser capture microdissected material of an ER+ tumor to
compare expression in whole-tissue vs. isolated cancer cell
expression.
The combination of the three genes TBP, RPLP0 and
PUM1 were repeatedly identified as the optimal reference
genes with the least variation among patient samples (for
IBC, both with or without normal tissue) by GeNorm. A
fourth, β-actin, was additionally required for the ER+ IBC
samples. Evaluating the samples as single entities, (i.e.
ER+ IBC, ER- IBC, normal or cell lines) rather than combi-
nations thereof did not significantly alter the most opti-
mal reference genes identified.
Various methods to compare RT-qPCR data have been
used since the initial development of real-time PCR in
1996 (reviewed by Hugget et al. in 2005 [5]). While it is
preferable to use internal reference genes, it is important
to note that some traditional reference genes may be reg-
ulated in certain settings, e.g. B2M in brain cortices of
human chronic alcoholics [6,20] and GAPDH in MCF-7
cells treated with estradiol [7]), which underscores the
importance of identifying appropriate reference genes
prior to the start of a study. The availability of easy-to-use,
dependable and freely available computer programs has
made it easier to identify optimal normalizers. The first of
these computer programs, geNorm [12], was reported in
Comparison of laser capture microdissected tumor cells and whole-tissue sectionsFigure 4
Comparison of laser capture microdissected tumor 
cells and whole-tissue sections. The correlation of the 
gene expression of the 4-group reference genes for laser 
capture microdissected (LCM) tumor cells vs. whole tissue 
sections of ER+ IBC was investigatedby Pearson analysis.
Stability value (NormFinder) for ER+ IBCs with sub-grouping based on prognostic factorsFigure 3
Stability value (NormFinder) for ER+ IBCs with sub-grouping based on prognostic factors. The sub-groups were 
defined as follows: Grades 1, 2, and 3. Size: above/below 20 mm. Positive lymph nodes: 0, 1–3 and >4. GAPDH should be used 
with caution since the primer-probe set used in this study have shown cross-reaction with pure genomic DNA.Page 8 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:20 http://www.biomedcentral.com/1471-2407/8/202002, shortly followed by NormFinder [13] in 2004.
Other statistical models to identify optimal reference
genes have now become available [18,21,22], but since
these are not freely available or easy to use, we focused on
geNorm [12] and NormFinder [13] in this study. A third
freely available program, BestKeeper, uses Pearson corre-
lation to calculate stable genes based on raw data [22].
This approach may be useful to narrow down a search if
no specific genes are known to be plausible candidates.
More advanced statistics are needed to rank the genes if
several are identified as good candidates, as provided by
geNorm and NormFinder.
Despite the use of programs to identify optimal normaliz-
ers, the difficulty of distinguishing between genes identi-
fied as stable and those being co-regulated in a given
experimental set-up remains. In addition, since the entire
biological function of most genes is not known, differen-
tiation of these groups cannot be delineated theoretically.
To decrease the likelihood of identifying a group of opti-
mal reference genes that are co-regulated, reference genes
located on different chromosomes and involved in differ-
ent basic cellular processes should be included. It has
been argued that NormFinder, with its model-based
approach that permits definition of sub-groups within the
investigated samples, is more precise than the pairwise
comparison approach used by geNorm [12], since the
former identifies co-regulated genes based on the similar-
ity of their expression profiles, and genes showing no dif-
ference between the sub-groups would be excluded early
in the pairwise comparison. This sub-group definition
option in NormFinder becomes most noteworthy when
looking for optimal reference genes across samples that
can differ in their hormonal states (ER+/ER- IBC) or
pathogenesis (cancer/normal tissue). Accordingly, we esti-
mate that in our study, where we sought to identify the
optimal reference genes within a homogenous population
of primarily ER+ IBC, geNorm and NormFinder without
using the option of sub-grouping, were equivalent in per-
formance, and therefore comparable. This assumption
was confirmed by the fact that both programs identified
the same top 4 genes, TBP, RPLP0, PUM1 and β-actin,
although in differing rank order, for all patient samples,
both in combination (geNorm) and as single entities
(NormFinder), strongly suggesting that these genes are
not influenced by hormonal status or general pathogene-
sis. Furthermore, defining prognostic sub-groups
(number of positive lymph nodes, malignancy grade or
tumor size) for the ER+ patients in NormFinder identified
the same top 4 genes with the smallest variation.
Although the low sample size does not allow a definitive
conclusion, it does show a tendency meriting further
investigation. An increase in aggressiveness has been
shown to influence which optimal gene to normalize
against for breast cancer cell lines [23], however this did
not seem to be the case for the patient samples and genes
evaluated in this study.
Another very important consideration when choosing ref-
erence genes is that the design of the primers and probes
accounts for possible pseudogenes or single-nucleotide
polymorphisms (SNPs). In addition, to prevent amplifica-
tion of contaminating gDNA, the amplicon should cross
exon-exon boundaries. An amplicon including an intron
is quite long and usually results in an incomplete tran-
script that does not contain the sequence for the reverse
primer, thereby preventing further amplification.
It is possible to use a gene that has pseudogenes if special
care is taken when selecting the cDNA region to be ampli-
fied, ensuring that the primers and probe sequences do
not have high homology to any gDNA sequences. This can
be investigated by a BLAT search [15], which was con-
ducted on the genes examined in this study (table 2), and
showed that the percentage of homology and the span of
the homologous region was acceptable. As this is a theo-
retical search, the primers and probe set must be tested for
reactivity to gDNA. Of the 4 selected genes, ACTB and
RPLP0 have known pseudogenes, but did not amplify
pure gDNA, which was circumvented by placing the prim-
ers and probe to target the 5'UTR. However, competitive
binding could not be avoided, as seen by the decreased
amplification efficiency when conducting a standard
curve using serial dilutions of cDNA in gDNA (Table 2).
Such decreased amplification efficiency is observed when
competitive binding occurs as the primer or probe cross-
reacts with gDNA when in excess, and thus the primers or
probe become limiting factors in the reaction. The oligo-
nucleotide binds to the wrong sequence and is subse-
quently elongated, rendering the primer or probe useless
and unavailable for amplification of the desired cDNA
sequence. In addition to choosing the optimal reference
gene(s) to normalize with, it is important to ensure that
only logarithmic amplification of the target occurs in the
reaction. If DNase treatment is omitted, and the primers
or probe bind to gDNA, linear amplification will occur,
resulting in a flawed Ct value if gDNA is in excess.
This pre-PCR step of DNase treatment is crucial when
employing reference genes known to cross-react with
gDNA in a competitive manner, since comparable ampli-
fication efficiencies are required to compare reference and
target genes. If this is not the case, a shift in the amplifica-
tion curve may be introduced that influences the ΔCt val-
ues. This can be exemplified by a primer-probe set with a
reduced efficiency of 1.5 compared to the ideal of 2.0,
resulting in a 104 difference in product amount after 30
cycles. If the primer and probe set amplifies gDNA with
resulting emission of fluorescence, they should not be
used as an assay for detection of either reference genes orPage 9 of 11
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DNase treatment is not 100%, and presence of gDNA,
although minor, will result in an incorrect, slightly higher
Ct value due to logarithmic amplification. Competitive
binding to gDNA, on the other hand, does not exclude the
use of the primer and probe set, as the DNase treatment
will decrease the amount of gDNA to such a degree that
the cDNA will be in significant excess and the use of prim-
ers or probe for unspecific sequences will be very small. In
addition, there will be no emission of fluorescence to
affect the Ct value. Competitive binding will therefore not
be an issue if DNase treatment is included. Thus, the
importance of including a DNase treatment step when
purifying RNA for RT-qPCR, including the 4 identified ref-
erence genes in this study, is apparent. In addition, special
care must be taken when using the ACTB or RPLP0 genes
as reference genes to be sure no gDNA amplification
occurs, since known pseuodogenes exist. This would lead
to over-estimation of the amount of input mRNA and
imprecise normalization of the target genes. For ACTB and
RPLP0, an amplicon crossing an exon-exon boundary
would not implicitly decrease the likelihood of amplifica-
tion of gDNA due to pseudogenes. When a DNase treat-
ment step was included in this study, the competitive
binding for these 2 of the top 4 reference genes was not an
issue, and as no amplification was seen for pure gDNA,
the Ct values measured for the top 4 reference genes were
specifically due to mRNA expression.
The presence of SNPs in most of the reference genes inves-
tigated should not be an excluding factor and SNPs prob-
ably exist in all genes. The presence of SNPs in candidate
reference genes should be revealed during testing of the
stability of the genes using the computer programs,
wherein the gene would appear up- or down-regulated
compared to other, stably-expressed, genes due to the var-
ying amplification efficiencies caused by mismatched
base pairs between the SNP-site(s) and the primers or
probe. The varying Ct values should result in elimination
of the gene as a suitable candidate.
The identification of reference genes is most often con-
ducted in a limited number of samples and the genes
should be re-evaluated after the end of the experiments,
preferably by one of the objective computer programs
including both the target and reference gene(s). It could
also be done by viewing the ΔCt between the reference
genes across all samples (as illustrated in Fig. 1), a method
that should result in a very small standard deviation.
Finally, the expression of the selected genes was evaluated
in consort with the various tissue components. Tissue sec-
tions of solid tumors contain various cell populations,
such as stroma, lymphocytes and tumor cells. Only minor
variations in gene expression of LCM-isolated tumor cells
compared to whole tissue was observed when examining
the 4-group reference genes for ER+ IBC. The Pearson cor-
relation was 0.992 (Fig. 4). The absolute difference
between tumor cells and whole tissue was 0.7 Ct, nearly
within the accepted technical variation of 0.5 Ct for RT-
qPCR.
Conclusion
The consistent identification of TBP, RPLP0 and PUM1
provides strong support for their use in RT-qPCR data nor-
malization of normal and malignant human breast sam-
ples. Based on geNorm, a fourth reference gene was
required when examining ER+ IBCs alone (β-actin). In
addition, the PCR characteristics were thoroughly evalu-
ated, emphasizing the need for a DNase pre-PCR treat-
ment step.
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